A Multicentric Castleman Disease Associated with Mixed Warm and Cold Antibody-Mediated AHA Responsive to Siltuximab.

IF 2 4区 医学 Q3 ONCOLOGY
Chemotherapy Pub Date : 2024-01-01 Epub Date: 2023-08-25 DOI:10.1159/000533235
Federica Plano, Salvatrice Mancuso, Giulia Maria Camarda, Maria Giulia Butera, Giuseppe Sucato, Giuseppe Alecci, Ada Maria Florena, Salvatore Perrone, Sergio Mario Siragusa
{"title":"A Multicentric Castleman Disease Associated with Mixed Warm and Cold Antibody-Mediated AHA Responsive to Siltuximab.","authors":"Federica Plano, Salvatrice Mancuso, Giulia Maria Camarda, Maria Giulia Butera, Giuseppe Sucato, Giuseppe Alecci, Ada Maria Florena, Salvatore Perrone, Sergio Mario Siragusa","doi":"10.1159/000533235","DOIUrl":null,"url":null,"abstract":"<p><p>Castleman disease is non-clonal lymphoproliferative disorders defined by hypertrophy of lymph nodes. The multicentric form (MCD), in which multiple lymph node stations are involved, is not associated with HHV8 infection, but considered idiopathic, although IL-6 appears to play a central role in its pathogenesis. Here, we report the case of a patient who presented with mixed autoimmune hemolytic anemia (AIHA) and adenopathy that was very challenging to diagnose due to very low values of hemoglobin and refractoriness of obtaining any improvement of AIHA with standard first and second lines of therapy (steroids, rituximab, immunoglobulin, erythropoietin, and cyclosporine). When we safely proceeded to lymph node biopsy, a diagnosis of MCD was established. This permitted the treatment with siltuximab, an anti-IL-6 monoclonal antibody. After only 1 week, hemoglobin raised and he was discharged. After 1 year, he was still in remission. This case underlines the challenges in diagnosis of MCD, and the first case of response to siltuximab after the failure of rituximab to relieve mixed AIHA.</p>","PeriodicalId":10047,"journal":{"name":"Chemotherapy","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000533235","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Castleman disease is non-clonal lymphoproliferative disorders defined by hypertrophy of lymph nodes. The multicentric form (MCD), in which multiple lymph node stations are involved, is not associated with HHV8 infection, but considered idiopathic, although IL-6 appears to play a central role in its pathogenesis. Here, we report the case of a patient who presented with mixed autoimmune hemolytic anemia (AIHA) and adenopathy that was very challenging to diagnose due to very low values of hemoglobin and refractoriness of obtaining any improvement of AIHA with standard first and second lines of therapy (steroids, rituximab, immunoglobulin, erythropoietin, and cyclosporine). When we safely proceeded to lymph node biopsy, a diagnosis of MCD was established. This permitted the treatment with siltuximab, an anti-IL-6 monoclonal antibody. After only 1 week, hemoglobin raised and he was discharged. After 1 year, he was still in remission. This case underlines the challenges in diagnosis of MCD, and the first case of response to siltuximab after the failure of rituximab to relieve mixed AIHA.

一种多中心卡斯特曼病,伴有对利妥昔单抗敏感的混合冷热抗体介导的AHA。
卡斯特曼病是一种以淋巴结肥大为特征的非克隆性淋巴组织增生性疾病。多中心型(MCD)累及多个淋巴结站,与 HHV8 感染无关,但被认为是特发性的,尽管 IL-6 在其发病机制中似乎起着核心作用。在此,我们报告了一例混合型自身免疫性溶血性贫血(AIHA)和腺病的患者,由于患者血红蛋白值非常低,而且在接受标准的一线和二线治疗(类固醇、利妥昔单抗、免疫球蛋白、促红细胞生成素和环孢素)后,AIHA症状仍未改善,因此诊断非常困难。当我们安全地进行淋巴结活检时,MCD 的诊断得以确立。因此,我们开始使用抗IL-6单克隆抗体西妥昔单抗(siltuximab)进行治疗。仅过了一周,血红蛋白就升高了,他也出院了。一年后,他的病情仍在缓解。该病例强调了诊断 MCD 所面临的挑战,也是首例在利妥昔单抗未能缓解混合型 AIHA 后对西妥昔单抗产生反应的病例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Chemotherapy
Chemotherapy 医学-药学
CiteScore
5.80
自引率
0.00%
发文量
34
审稿时长
6-12 weeks
期刊介绍: This journal publishes original research articles and state-of-the-art reviews on all aspects of antimicrobial and antitumor chemotherapy. The results of experimental and clinical investigations into the microbiological and pharmacologic properties of antibacterial, antiviral and antitumor compounds are major topics of publication. Papers selected for the journal offer data concerning the efficacy, toxicology, and interactions of new drugs in single or combined applications. Studies designed to determine the pharmacokinetic and pharmacodynamics properties of similar preparations and comparing their efficacy are also included. Special emphasis is given to the development of drug-resistance, an increasing problem worldwide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信